In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Increased adipose tissue bradykinin receptors gene expression profiles in obese patients with coronary artery disease

Session Poster session 4

Speaker Maria Marketou

Event : ESC Congress 2016

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease and Comorbidities
  • Session type : Poster Session

Authors : M Marketou (Heraklion,GR), G Kochiadakis (Heraklion,GR), J Kontaraki (Heraklion,GR), E Zacharis (Heraklion,GR), K Roufas (Heraklion,GR), S Maragkoudakis (Heraklion,GR), F Parthenakis (Heraklion,GR), A Patrianakos (Heraklion,GR), D Vougia (Heraklion,GR), J Logakis (Heraklion,GR), P Vardas (Heraklion,GR)

Authors:
M. Marketou1 , G. Kochiadakis1 , J. Kontaraki1 , E. Zacharis1 , K. Roufas1 , S. Maragkoudakis1 , F. Parthenakis1 , A. Patrianakos1 , D. Vougia1 , J. Logakis1 , P. Vardas1 , 1Heraklion University Hospital - Heraklion - Greece ,

Citation:
European Heart Journal ( 2016 ) 37 ( Abstract Supplement ), 773

Purpose: Adipose tissue is an inflammatory source of coronary artery disease (CAD). Kinin receptors may be an important determinant of the impact of adiposity on endothelial function and cardiovascular function. The aim of this study was to examine kinin receptors gene expression levels in the adipose tissue in obese patients with and without CAD.

Methods: Obese patients (BMI >30kg/m2) undergoing coronary angiogram were participated in the study. We included 15 patients with CAD (9 male, 64±8 years old) and 9 patients without CAD (6 male, 63±8 years old). Subcutaneous white adipose tissue biopsies were obtained from the site of paracentesis before the procedure and analyzed for bradykinin receptor type 1 (BR1) and 2 (BR2) gene expression by RT-quantitative PCR.

Results: Adipose tissue analysis revealed increased BR1 and BR2 gene expression levels in obese patients with CAD compared to those without CAD. More specifically, BR1 gene expression levels were 654±345 in patients with CAD versus 107±99 in patients without CAD and BR2 gene expression levels were 458±165 in patients with CAD versus 133±107 in patients without CAD (p<0.05 for both). No statistical significant correlation were found between BR1 and BR2 gene expression levels and patients' BMI.

Conclusions: There is a divergence in BR1 and BR2 gene expression in adipose tissue between obese patients who exhibit or do not exhibit CAD. Our findings may have implications in the pathophysiology and treatment of atherosclerosis and should be further investigated.

This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are